STTCOMP ACW, FA Long
Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Market Cap: $38m / Cash: $5.5m
Detailed Description/Catalyst
Top 20 shareholders own 49% of the company.
No1 shareholder owns 6.81% and concept of this drug was first discovered by them, by accident, giving then the best possible position to make a call on this drug. As such they have come on board and taken the biggest stake at No1.
At Phase 2 testing and human trials have already been inadvertently tested.
Taken from the most recent presentation:
I attended their recent road show in Melbourne and I was sold by the story.
Best bet is to read their most recent presentation as it details the story fairly well.
***DISCLAIMER: Don’t take as financial advice as I am not qualified/licenced to give it.***
STTCOMP ACW, FA Long Actinogen Medical is an ASX-listed...
Add XAO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8,586.9 |
Change
-23.500(0.27%) |
Mkt cap ! n/a | |||
| Open | High | Low |
| 8,610.4 | 8,644.8 | 8,585.3 |
| XAO (ASX) Chart |